556 results on '"Orlando, A."'
Search Results
2. Transition care in patients with IBD: The pediatric and the adult gastroenterologist's perspective. Results from a national survey
3. Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study
4. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
5. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
6. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease
7. A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis
8. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology
9. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology
10. Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy
11. Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: A single-arm meta-analysis of observational studies
12. Female reproductive health and inflammatory bowel disease: A practice-based review
13. OC.07.5: BOWEL URGENCY IN PATIENTS WITH ULCERATIVE COLITIS: PREVALENCE AND ASSOCIATION WITH CLINICAL, ENDOSCOPIC DATA AND DISABILITY
14. OC.07.3: CORTICOSTEROID-SPARING EFFECT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB MAINTENANCE THERAPY
15. OC.18.7: HIDDEN SHORT BOWEL SYNDROME IN CROHN'S DISEASE: A NATIONAL SURVEY
16. OC.07.2: ASSESSMENT OF VEDOLIZUMAB AND USTEKINUMAB IN ELDERLY (AVENUE) PATIENTS WITH CROHN'S DISEASE (CD): AN IG-IBD STUDY
17. OC.03.9: IBD-DISK: ITALIAN TRANSLATION AND VALIDATION IN A POPULATION-BASED COHORT
18. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases
19. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis
20. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases
21. COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data
22. Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease
23. Analysis of patients attitude to undergo urgent endoscopic procedures during COVID-19 outbreak in Italy
24. Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality
25. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign
26. Follow-up evaluation and management of anemia in inflammatory bowel disease: A study by the Italian Group for Inflammatory Bowel Diseases (IG-IBD)
27. Transition care in patients with IBD: The pediatric and the adult gastroenterologist's perspective. Results from a national survey
28. Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants
29. Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology
30. Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems
31. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
32. Risk factors and timing for colectomy in chronically active refractory ulcerative colitis: A systematic review
33. Translation and initial validation of the Medication Adherence Report Scale (MARS) in Italian patients with Crohn’s Disease
34. Diagnosis of chronic anaemia in gastrointestinal disorders: A guideline by the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Society of Paediatric Gastroenterology Hepatology and Nutrition (SIGENP)
35. Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study
36. Unmet needs of Italian physicians managing patients with inflammatory bowel disease
37. Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study
38. Author's reply: “Tofacitinib in ulcerative colitis—Small molecule but large effect”
39. Ustekinumab in the management of Crohn’s disease: Expert opinion
40. Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts
41. Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study
42. Sarcopenia is a negative predictive factor for endoscopic remission in patients with Crohn's disease treated with biologics
43. Nurse in patients’ health status assessment: Data from a pilot study assessing agreement among nurse and gastroenterologist in computing IBD-clinical scores
44. Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease
45. Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)
46. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease
47. Use of biologics for the management of Crohn's disease: IG-IBD clinical guidelines based on the GRADE methodology
48. OC.14.2 LACK OF SEROCONVERSION FOLLOWING COVID-19 VACCINATION, BUT NOT TREATMENT, IS AN INDEPENDENT RISK FACTOR FOR BREAKTHROUGH SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: DATA FROM ESCAPE - AN IGIBD STUDY
49. T.06.2 USTEKINUMAB IS A PROMISING OPTION FOR THE TREATMENT OF POSTOPERATIVE RECURRENCE OF CROHN'S DISEASE
50. OC.14.6 ATTITUDES TOWARDS VACCINATIONS IN AN ITALIAN COHORT OF IBD PATIENTS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.